Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie B Dumond

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Pharmacotherapy|February 13, 2025
Intracellular dried blood spot metabolite concentrations for assessing antiretroviral adherence and HIV progressionJulie B Dumond
The Lancet. HIV|December 4, 2018
The potential pitfalls of PrEPMackenzie L Cottrell, Julie B Dumond
AIDS (London, England)|October 3, 2019
Déjà vu all over againMichael S Saag, Julie B Dumond
JAMA|March 1, 2024
Shifting the Narrative of Preexposure Prophylaxis Adherence Counseling for Cisgender WomenAnandi N Sheth, Florence Momplaisir, Julie B Dumond
Journal of Pharmacokinetics and Pharmacodynamics|November 10, 2017
Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed dataJon W Collins, J Heyward Hull, Julie B Dumond
The Journal of Infectious Diseases|February 18, 2026
Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV PreventionNathan Engel, Julie B Dumond, Angela D M Kashuba, et al.
Lancet (London, England)|December 14, 2011
Pre-exposure prophylaxis for HIV prevention: how to predict successAngela Dm Kashuba, Kristine B Patterson, Julie B Dumond, et al.
Clinical Pharmacology and Therapeutics|September 26, 2024
Lenacapavir: Playing the Long Game in the New Era of AntiretroviralsNoah C Neverette, Julie B Dumond, Deborah K McMahon, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 10, 2023
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV preventionErick Leung, Mackenzie L Cottrell, Craig Sykes, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2026
Contemporary antiretroviral pharmacology in the male genital tract: implications for HIV treatment and preventionNoah C Neverette, Jordan Winfield, Nathalia Chaparro-Cáceres, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Pharmacotherapy|February 13, 2025
Intracellular dried blood spot metabolite concentrations for assessing antiretroviral adherence and HIV progressionJulie B Dumond
The Lancet. HIV|December 4, 2018
The potential pitfalls of PrEPMackenzie L Cottrell, Julie B Dumond
AIDS (London, England)|October 3, 2019
Déjà vu all over againMichael S Saag, Julie B Dumond
JAMA|March 1, 2024
Shifting the Narrative of Preexposure Prophylaxis Adherence Counseling for Cisgender WomenAnandi N Sheth, Florence Momplaisir, Julie B Dumond
Journal of Pharmacokinetics and Pharmacodynamics|November 10, 2017
Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed dataJon W Collins, J Heyward Hull, Julie B Dumond
The Journal of Infectious Diseases|February 18, 2026
Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV PreventionNathan Engel, Julie B Dumond, Angela D M Kashuba, et al.
Lancet (London, England)|December 14, 2011
Pre-exposure prophylaxis for HIV prevention: how to predict successAngela Dm Kashuba, Kristine B Patterson, Julie B Dumond, et al.
Clinical Pharmacology and Therapeutics|September 26, 2024
Lenacapavir: Playing the Long Game in the New Era of AntiretroviralsNoah C Neverette, Julie B Dumond, Deborah K McMahon, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 10, 2023
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV preventionErick Leung, Mackenzie L Cottrell, Craig Sykes, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2026
Contemporary antiretroviral pharmacology in the male genital tract: implications for HIV treatment and preventionNoah C Neverette, Jordan Winfield, Nathalia Chaparro-Cáceres, et al.
Pageof 5